This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Novavax Shares Pop Another 50% Following Sanofi Deal DJ
Top Midday Stories: Return of 'Roaring Kitty' Lifts GameStop Shares; Intel, Apollo Near Deal on Ireland Plant; BHP Latest Offer Rejected by Anglo American; Squarespace Acquired by Permira; Amazon Autonomous Driving Under Probe MT
CAC40: symbolic losses, 'volat' rises at W-Street CF
Trending : Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal DJ
Sartorius Partners With Sanofi for Biomanufacturing Platform MT
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- 2nd Update DJ
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit -- Update DJ
Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment MT
Sanofi to Invest $1.08 Billion Into Three French Drug Manufacturing Sites MT
Sanofi Signs License Deal for Rare Genetic Muscle Disease Drug MT
Sanofi to Invest $1.08 Billion Into 3 French Drug Manufacturing Sites MT
SANOFI : Sell rating from Deutsche Bank ZD
Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal DJ
SANOFI : Berenberg maintains a Buy rating ZD
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group DJ
France Secures Billions at Foreign Investment Summit DJ
CAC40: stable at the start of a week packed with indicators CF
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review MT
Sanofi to Spend $1.08 Billion to Boost Drug Production in France DJ
Sanofi invests 1.1 billion euros in France CF
Sanofi Plans EUR1 Billion Investments in France MT
Sanofi pledges new 1 bln euros worth of investments in French production sites RE
News Highlights : Top Company News of the Day - Friday at 7 PM ET DJ
Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup DJ
US Equity Markets Close Mixed Friday After Consumer Sentiment Falls MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
94.33 EUR
Average target price
108.3 EUR
Spread / Average Target
+14.85%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi : Secures mRNA Boost With $3.2 Billion Translate Bio Purchase
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW